CSW Industrials vs Ingevity
CSW and NGVT side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CSW and NGVT compare
CSW Industrials is the larger company, worth 2.2 times as much as Ingevity ($4.6B against $2.1B).
On earnings, Ingevity is cheaper: it trades at 36.3× trailing earnings, against 36.4× for CSW Industrials.
CSW Industrials grew revenue faster over the last twelve months (30.0% versus −3.7% for Ingevity).
CSW Industrials keeps more of each dollar of sales as profit, with a net margin of 10.2% compared with 5.3% at Ingevity.
CSW Industrials pays a dividend yielding 0.31%; Ingevity does not pay one.
CSW Industrials scores higher on the StockData Score (10 against 6 for Ingevity), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CSW | NGVT |
|---|---|---|
| Size and price | ||
| Market cap | $4.6B | $2.1B |
| Share price | $283.04 | $61.72 |
| Change, 1 year | 15.5% | 25.6% |
| Change, 5 years | 105% | −21.7% |
| Beta (5Y) | 1.01 | 1.21 |
| Employees | 2,700 | 1,500 |
| StockData Score | ||
| Total score | 10 (better) | 6 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 2 | 3 (better) |
| Health score | 3 (better) | 1 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 36.4× | 36.3× (better) |
| P/S | 3.7× | 1.9× (better) |
| P/B | – | 33.7× |
| EV/EBITDA | 25.2× | 23.1× (better) |
| P/FCF | 26.0× | 17.3× (better) |
| PEG | 13.89 | – |
| FCF yield | 3.8% | 5.8% (better) |
| Fair value | $208.91 | $35.71 |
| Margin of safety | −35.5% (better) | −72.8% |
| Growth | ||
| Revenue growth (TTM) | 30.0% (better) | −3.7% |
| Revenue growth, 5Y average | 20.9% (better) | −0.81% |
| Net income growth (TTM) | −11.2% | – |
| EPS growth (TTM) | −8.7% | – |
| EPS growth, 5Y average | 20.4% | – |
| Profitability | ||
| Gross margin | 42.1% (better) | 42.0% |
| Operating margin | 16.9% | – |
| Net margin | 10.2% (better) | 5.3% |
| FCF margin | 14.2% (better) | 10.8% |
| Return on equity | – | 59.5% |
| Financial health | ||
| Debt / equity | – | 18.18 |
| Net debt / EBITDA | 3.43 (better) | 7.68 |
| Current ratio | 2.35 (better) | 1.48 |
| Altman Z-score | 3.88 (better) | 2.29 |
| Piotroski F-score | 3 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.31% | – |
| Payout ratio | 14.7% | – |
| Buyback yield | 3.2% | 7.4% (better) |
| Shareholder yield | 3.5% | 7.4% (better) |
| Ownership | ||
| Held by institutions | 101% | 102% |
| Held by insiders | 1.4% | 1.4% |
| Insider net buying, 12 months | −$8.7M | −$1.8M (better) |
| Short interest, % of float | 6.3% | 3.7% |
Go deeper
- CSW stock overview
- CSW income statement
- CSW valuation and score
- NGVT stock overview
- NGVT income statement
- NGVT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.